Aggressive Vaccine-Induced Immune Thrombocytopenia and Thrombosis in a Young Woman with a Past Mild SARS-CoV-2 Infection

Aggressive Vaccine-Induced Immune Thrombocytopenia and Thrombosis in a Young Woman with a Past Mild SARS-CoV-2 Infection

Vaccine- induced immune thrombocytopenia and thrombosis (VITT) is a rare adverse event occurring after immunization with adenoviral vector-based vaccines against SARS-CoV-2. This life-threatening condition is characterized by thrombocytopenia, systemic activation of coagulation, and anti-platelet fa...

Full description

Bibliographic Details
Main Authors:	Filippo Luciani, Maria Cristina Caroleo, Alfredo Zanolini, Lucio Taranto, Pino Pasqua, Alfredo Petrone, Manuela Colosimo, Roberto Cannataro, Erika Cione
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Reports
Subjects:	VITT ChAdOx1 nCov-19 vaccine stroke transtentorial uncal herniation
Online Access:	https://www.mdpi.com/2571-841X/7/1/17

Similar Items

Transjugular intrahepatic portosystemic shunt, local thrombaspiration, and lysis for management of fulminant portomesenteric thrombosis and atraumatic splenic rupture due to vector-vaccine-induced thrombotic thrombocytopenia: a case report
by: Sandra Emily Stoll, et al.
Published: (2022-07-01)

Case Report: Hypergranular Platelets in Vaccine-Induced Thrombotic Thrombocytopenia After ChAdOx1 nCov-19 Vaccination
by: Shane P. Comer, et al.
Published: (2022-02-01)

Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)—Insights from Clinical Cases, In Vitro Studies and Murine Models
by: Venkata A. S. Dabbiru, et al.
Published: (2023-09-01)

A case report of vaccine-induced immune thrombotic thrombocytopenia (VITT) with genetic analysis
by: Daniela P. Mendes-de-Almeida, et al.
Published: (2023-05-01)

Vaccine‐induced prothrombotic immune thrombocytopenia without thrombosis may not require immune modulatory therapy: A case report
by: Chieh Min Benjamin Lai, et al.
Published: (2022-05-01)

Palatal petechiae: an uncommon oral adverse effect of COVID-19 vaccine
by: Bhawna Sayare, et al.
Published: (2021-09-01)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
by: Jer-Hwa Chang, et al.
Published: (2022-02-01)

Potential Anionic Substances Binding to Platelet Factor 4 in Vaccine-Induced Thrombotic Thrombocytopenia of ChAdOx1-S Vaccine for SARS-CoV-2
by: Xiaocong Pang, et al.
Published: (2022-01-01)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
by: Josue Antonio Estrada, et al.
Published: (2022-04-01)

Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues
by: Anita Badbaran, et al.
Published: (2021-12-01)

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults
by: Prasad S. Kulkarni, et al.
Published: (2024-12-01)

Falco-tentorial meningioma producing irreversible midbrain damage
by: Amit Agrawal
Published: (2014-09-01)

Upward transtentorial herniation
by: Nidal B. Omar, et al.
Published: (2020-12-01)

CT perfusion illustrated reversal of uncal herniation after placement of an external ventricular drain
by: Ulus Baran, MD, et al.
Published: (2015-12-01)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
by: Jinnam Kim, et al.
Published: (2023-04-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
by: Tamara Garibashvili, et al.
Published: (2022-06-01)

A case of Vaccine-Induced Thrombotic Thrombocytopenia (VITT) with thrombosis of the superior mesenteric artery after ChAdOx1 nCov-19 COVID-19 Vaccine
by: Laura Pini, et al.
Published: (2021-12-01)

Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia
by: Victoria Panagiota, et al.
Published: (2022-08-01)

Covid Antibody Titers in Cancer Patients Following Vaccination with ChAdOx1 nCOV-19 Vaccine
by: Ashish Chavan, et al.

Fatal myositis, rhabdomyolysis and compartment syndrome after ChAdOx1 nCoV-19 vaccination
by: Szu-Ting Huang, et al.
Published: (2022-12-01)

Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study
by: Nattaya Teeyapun, et al.
Published: (2022-10-01)

Case Report: Take a Second Look: Covid-19 Vaccination-Related Cerebral Venous Thrombosis and Thrombotic Thrombocytopenia Syndrome
by: Tobias Braun, et al.
Published: (2021-11-01)

Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination
by: Jimin Hwang, et al.
Published: (2022-03-01)

Relapse of immune thrombocytopenia after receiving AstraZeneca coronavirus disease‐2019 vaccine: A case report
by: Saba Seyedi, et al.
Published: (2023-09-01)

Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers
by: Najlaa Assaid, et al.
Published: (2022-03-01)

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19
by: Jie Wei, et al.
Published: (2023-02-01)

Case report: Early onset Marin-Amat syndrome after receiving ChAdOx1 nCoV-19 vaccination
by: Ping-Feng Tsai, et al.
Published: (2022-11-01)

Active surveillance of adverse events following ChAdOx1 nCoV-19 immunization in geriatric population: a prospective multi-centric study from Jaipur, Rajasthan, India
by: Anil Bhandari, et al.
Published: (2022-01-01)

Cutaneous leukocytoclastic vasculitis following COVID‐19 vaccination
by: Manuel Zoppi, et al.
Published: (2023-12-01)

Acute Polyserositis with Cardiac Tamponade and Bilateral Refractory Pleural Effusion after ChAdOx1 nCoV-19 Vaccination
by: Guan-Yi Li, et al.
Published: (2022-08-01)

An Insight into the Role of Postmortem Immunohistochemistry in the Comprehension of the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-Related Thrombotic Adverse Events: A Narrative Review
by: Chiara Stassi, et al.
Published: (2021-11-01)

Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
by: Minji Jeon, et al.
Published: (2021-09-01)

A Single Dose of ChAdOx1 nCoV-19 Vaccine Elicits High Antibody Responses in Individuals with Prior SARS-CoV-2 Infection Comparable to That of Two-Dose-Vaccinated, SARS-CoV-2-Infection-Naïve Individuals: A Longitudinal Study in Ethiopian Health Workers
by: Tesfaye Gelanew, et al.
Published: (2022-05-01)

Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021
by: Yao Rodion Konu, et al.
Published: (2021-11-01)

Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review
by: Chia-Tung Wu, et al.
Published: (2022-04-01)

A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy
by: Raffaele Palladino, et al.
Published: (2021-06-01)

Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer
by: Seri Jeong, et al.
Published: (2021-12-01)

ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis
by: Wisit Prasithsirikul, et al.
Published: (2022-06-01)

Platelet Activation and Cytokine Release of Interleukin-8 and Interferon-Gamma-Induced Protein 10 after ChAdOx1 nCoV-19 Coronavirus Vaccine Injection
by: Chih-Lung Shen, et al.
Published: (2023-02-01)

Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2– seropositive individuals
by: Edgar Ruz Fernandes, PhD, et al.
Published: (2023-05-01)